top of page

Day 32 Johnson & Johnson

Pharmaceutical giant Johnson & Johnson is partnering with the US government to battle the Coronavirus. The Biomedical Advanced Research and Development Authority (BARDA) was already supporting Johnson & Johnson's efforts to find a vaccine that could protect people from the coronavirus. Now, it will also support the company's attempt to develop antiviral medications that could help people already infected with it.

J&J is setting a goal of providing a global supply of more than one billion doses of the vaccine, which it expects to have in clinical trials by September 2020 at the latest. The first batches of the vaccine may be available for emergency use by early 2021, the company said.

Janssen Pharmaceutical, a Belgian subsidiary of J&J already has a library of antiviral compounds that it can screen to see if they could potentially be active against COVID-19. Janssen is partnering with the Rega Institute for Medical Research from the KULeuven University in Belgium to perform the screening.


Recent Posts

See All

Belgium is conducting a large-scale trial with the plasma of recovered COVID-19 patients. The trial is a collaboration between hospitals in Flanders and is coordinated by UZ (University Hospital) Leuv

Astrazeneca, the British – Swedish drug maker, has joined forces with the UK government to support the Oxford University to develop a coronavirus vaccine. The partnership is one the most closely watch

Tresorit, a start up from Switzerland, empowers medical professionals and education institutions with a highly secure way to store and share information. COVID-19 has significantly changed and challen

bottom of page